Screener
Stoke Therapeutics, Inc. STOK Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211874
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accounts payable | $6,839 | $4,939 |
| Accrued and other current liabilities | 23,901 | 41,035 |
| Deferred revenue - current portion | 10,066 | 11,901 |
| Total current liabilities | $40,806 | $57,875 |
| Deferred revenue - net of current portion | 6,603 | 6,961 |
| Other long-term liabilities | 991 | 1,141 |
| Total long-term liabilities | 7,594 | 8,102 |
| Total liabilities | $48,400 | $65,977 |
Item 1. Financial Statements.
FAQ
- What is Stoke Therapeutics, Inc.'s total current liabilities?
- Stoke Therapeutics, Inc. (STOK) reported total current liabilities of $40.81M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s total current liabilities changed year-over-year?
- Stoke Therapeutics, Inc.'s total current liabilities decreased by 8.7% year-over-year, from $44.69M to $40.81M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Stoke Therapeutics, Inc.'s total current liabilities has grown at a 38.3% compound annual growth rate (CAGR), from $11.43M to $57.88M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Stoke Therapeutics, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude